secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0001493152-24-014069
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx raises $11.1M via private placement of shares and warrants; funds Phase III trial into 2026
--------------------------------------------------------------------------------

- Gross proceeds of ~$11.1M from sale of 7,912,364 shares and warrants at $1.4075 per unit.
- Warrants include Series A (5-year, $1.22 strike) and Series B (2-year, $1.22 strike), 150% warrant coverage.
- Cash runway extended into 2026; combined with prior $6.1M Jan 2024 financing.
- Proceeds fund pivotal Phase III TIGeR-PaC trial through second interim readout (est. late 2024).
- Financing also enables expansion of TAMP clinical pipeline into additional cancer indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315224014069/0001493152-24-014069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315224014069/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer